// App-Quantinova.ai

1640 : Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Researchers

Presenter

  • Vaishali Sanchorawala

Principal Investigators

  • Monique C. Minnema

  • Arnaud Jaccard

  • Hans C. Lee

  • Simon D. Gibbs

  • Peter Mollee

  • Christopher P. Venner

  • Jin Lu

  • Stefan Schnland

  • Moshe Gatt

  • Kenshi Suzuki

  • Kihyun Kim

  • M. Teresa Cibeira

  • Meral Beksac

  • Edward Libby

  • Jason Valent

  • Vania T. M. Hungria

  • Sandy W. Wong

  • Michael Rosenzweig

  • Naresh Bumma

  • Dominique Chauveau

  • Katharine S. Gries

  • John Fastenau

  • NamPhuong Tran

  • Xiang Qin

  • Sandra Y. Vasey

  • Brenda Tromp

  • Brendan M. Weiss

  • Jessica Vermeulen

  • Giampaolo Merlini

  • Raymond L. Comenzo

  • Efstathios Kastritis

  • Ashutosh D. Wechalekar

Medical Centers

  • Section of Hematology and Oncology, Boston Medical Center and Boston University School of Medicine, Boston, MA

  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

  • University Medical Center Utrecht, Utrecht, Netherlands

  • CHU de Limoges - Fédération Hépatologie, Limoges, France

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Box Hill Hospital, Box Hill, Australia

  • Princess Alexandra Hospital, Woolloongabba, Australia

  • Alberta Health Services (AHS), Edmonton, Canada

  • Peking University People's Hospital, Beijing, China

  • Universitaetsklinikum Heidelberg Medizinische Klinik V, Heidelberg, Germany

  • Hadassah Medical Center, Jerusalem, Israel

  • Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan, Tokyo, Japan

  • Sungkyunkwan university school of medicine, samsung medical center, Seoul, Korea (the Republic of)

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Turkey

  • Seattle Cancer Care Alliance, Seattle, WA

  • Cleveland Clinic, Cleveland, OH

  • Sao Germano Clinic, Sao Paulo, Brazil

  • University of California, San Francisco, San Francisco, CA

  • City of Hope, Duarte, CA

  • The Ohio State Univerisity, Columbus, OH

  • Hopital Rangueil, Toulouse, France

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, Leiden, Netherlands

  • Janssen Research & Development, Leiden, Netherlands

  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

  • Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • General Hospital of Athens, Athens, Greece

  • Kings College London, London, United Kingdom

Locations

  • United States

  • Italy

  • Netherlands

  • France

  • Australia

  • Canada

  • China

  • Germany

  • Israel

  • Japan

  • Republic of South Korea

  • Spain

  • Turkey

  • Brazil

  • Greece

  • United Kingdom

Companies

  • JB Medical Ltd.

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • AL Amyloidosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

  • Sparsentan

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03201965

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved